#1KHIRON LIFE SCIENCES CORP PATIENT-FOCUSED, GLOBAL CANNABIS COMPANY FROM LATIN AMERICA TSXV: KHRN | OTCQX: KHRNF | FRANKFURT: A2 JMZC October 2020#2KHIRON LARI Legal Notices This information in this presentation is current as of September 9, 2020 unless otherwise indicated. The information contained in this presentation is provided for informational purposes only and does not constitute an offer issue or arrange to issue, or the solicitation of an offer to issue, securities of Khiron. No part of this presentation shall form the basis or be relied upon in connection with any contract, commitment or investment decisions in relation thereto. The information contained herein is not investment advice and is not intended to be used as the basis for making an investment decision. No securities commission or similar regulatory authority in Canada has reviewed this presentation. Investors and prospective investors should rely only on the information contained in the continuous disclosure filings of Khiron on www.SEDAR.com under Khiron's issuer profile. This presentation is qualified in its entirety by reference to, and must be read in conjunction with, such filings. This presentation contains "forward-looking statements," within the meaning of applicable Canadian securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, assumptions and analyses made by us regarding the future of our business, future plans and strategies, our operational results and other future conditions. These forward-looking statements appear in a number of places throughout this presentation and can be identified by the use of words, such as "anticipates," or "believes," "budget," "estimates," "expects," or "is expected," "forecasts," "intends," "plans," "scheduled," or variations of such words and phrases or state that certain actions, events or results "may," "might," "will," "would," "could", "should," "continue," or be taken, occur or be achieved. These forward-looking statements relate to, among other things, our future financial performance, financial condition, liquidity, levels of activity, performance, prospects, growth, goals or achievements or other future events. Although we base the forward-looking statements contained in this presentation on assumptions that we believe are reasonable, these forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual performance and financial results in future periods to differ materially from those anticipated in our forward-looking statements, including those risk factors identified in Khiron's most recent MD&A, AIF and other disclosure documents available on SEDAR at www.SEDAR.com under Khiron's issuer profile. Forward- looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made have on our business. For example, they do not include the effect of asset impairments or other charges announced or occurring after the forward-looking statements are made. The financial impact of such transactions and non-recurring and other special items can be complex and necessarily depends on the facts particular to each of them. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. The purpose of the forward-looking statements is to provide the reader with a description of management's expectations regarding our anticipated future performance and may not be appropriate for other purposes. Furthermore, unless otherwise stated, the forward-looking statements contained in this report are made as of the date of this report and we do not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise unless required by applicable legislation or regulation. The forward-looking statements contained this document are expressly qualified by this cautionary statement. Market Research and Public Data: This corporate presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although we believe these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. We have not independently verified any of the data from third party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed. Future Oriented Financial Information: To the extent any forward-looking information in this corporate presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future- oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above. Our actual financial position and results of operations may differ materially from management's current expectations and, as a result, our revenue and profitability may differ materially from the revenue and profitability profiles provided in this corporate presentation. Such information is presented for illustrative purposes only and may not be an indication of our actual financial position or results of operations. Use of Non-GAAP Measures: This document refers to certain financial performance measures that are not defined by and do not have any standardized meaning under GAAP and are used by management to assess the financial and operational performance of the Company, including EBITDA, because certain investors may use this information to assess our performance and also determine our ability to generate cash flow. This data is furnished to provide additional information and are non-GAAP measures and do not have any standardized meaning prescribed by GAAP. They should not be considered in isolation as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of operating costs presented under GAAP.#3KHIRON is a pureplay health & wellbeing company in the rapidly growing global cannabis market Our Mission Verenia DD To improve the quality of life of patients and consumers through the applied use of cannabis 1st company to reach more than 3,500 medical cannabis prescriptions in Colombia, combining a traditional pharma approach, wholly-owned clinics and telehealth solutions First Latam Company with medical cannabis scripts in the UK and soon in Germany (High and Low THC) 2 Our Vision DDD To reach 1 million patients and consumers by 2024 450% QOQ growth in Colombian medical cannabis prescriptions in Q3/20 vs Q2/20 KHIRON LITT SEITACTS CORE 1st company to sell approved medical cannabis products in Peru through pharmacy chains 11 SKUs of CBD-based CPG products in 4 continents#4Khiron's Market Opportunity Medical Cannabis 86.0 $28.9 Million Patients US$ Billion KHIRON 18 68 LatAm Europe 22 Patients Market (Million Patients) (US$ Billions) in 2024 7 KHIRON MED Sources: Prohibition Partners Global Cannabis Report, Nov 2019, European Cannabis Report, 5th Edition. Mgmt estimates on patient base % Potential Patients by Condition in Latin America 3 Unique approach to patient acquisitions by focusing on relationships & education 12% 8% 9% 17% --53% Chronic Pain Depression Other Sources: Management own estimates by IMS Quantiles Anxiety Epelepsy KHIRON Prasaden KHIRON Ir SciTNCS CORP பண்டை * de Magd tow KHIRON Preparación Magistral SERGE 45524#5B2C Focus: Brands, not grams 01/01/2011 K X →Starbucks USD/share Source: Finance Yahoo SBUX, https://www.macrotrends.net/2535/coffee-prices-historical-chart-data KHIRON LIFE SCIENCES CORP -O-Coffee Spot Price (USD/Lb) 个 255% $ 65.7/share 01/01/2012 01/01/2013 01/01/2014 01/01/2015 01/01/2016 01/01/2017 01/01/2018 01/01/2019 ABUCK COFFEL ↓ 54% $ 1.2/Lb#6Go to Market Medical Strategy KHIRONMED Havem para la prescipita ku Grub Khiero Locatel nimbus HEALTH 00 O ✓ High quality medical cannabis products Stabilized and consistent with multiple concentration ratios and presentations KHIRON LIFE SCIENCES CORP ✓ Doctor education to drive prescriptions Generating brand loyalty and awareness by engaging doctors through continuing education ✓ Wholly-owned clinics Owning or partnering exclusively with 3rd party clinics for direct patient access, data, and business analytics to generate evidence. ✓ Accessible telehealth for all Telehealth platforms to connect doctors and patients in the low-touch economy (15% of consults through telehealth) ✓ Khiero patient program CUERPO 1st multi-jurisdiction medical cannabis patients' program in Peru and Colombia with more than 1,500 subscribers ✓ Focus on distribution Partner early with established distributors / pharmacies to increase accessibility SP 01 5#71st Company to Prescribe and Sell Low and High-THC Medical Cannabis in Colombia 49.1 M Population Production 5 Ha cultivation site in Colombia, including 14,000 sq. ft INVIMA GMP-GEP compliant extraction facility * US$ 1.6B Colombia medical cannabis TAM¹ Education KHIRON MED per la prescripció de cada p Sp 00 O O ON24 Online physician and doctor education platforms to bring awareness and drive prescriptions 5.6 Million Current patients with applicable conditions² Prescriptions Zerenia AGENDA TU CITA MEDICA O TELECONSULTA LLAMANDO A 300 412 8179-301 283 5413 CUERPO MENTEY ESPIRITU CANNABIS * US$ 370 / yr Estimated annual patient out-of-pocket expenditure on medical cannabis³ Three wholly-owned clinics with more than 9,000 medical transaction per month and more than 450% QOQ growth in medical cannabis prescriptions. 15% of cannabis prescriptions associated with telehealth platform. KHIRON LIFE SCIENCES CORP Distribution dooo KAIRON LIFE SCIENCE Partnerships with more than 15 third party clinics and health centres improves patient access across Colombia 1-New Frontier Data. The Latin America Regional Cannabis Report 2019 Industry Outlook, 2- Mgmt estimates from IMS Quantiles study, 3- Mgmt own estimates Medical transactions include consultation, surgical procedure, therapeutic support, diagnostic service, etc 6#8World-class Operations & Supply Chain Cultivation & Extraction Fully licensed for commercial THC and CBD cultivation, extraction & sales in Colombia Total area of 20 Ha. Current cultivation area of 80,000 sq.ft. Obtained 17% of Colombia's total allocation of THC quotas for 2020. 1st company to do so in Colombia State-of-the-art, 14,000 sq.ft. GMP-compliant post-harvest facility in Doima, Colombia (157 Km west of Bogota) Production Capacity³ Cultivation: Upwards of 9 tonnes¹ of dry flower Extraction: Up to 3 tonnes of full-spectrum extract², with capacity to expand within building ~1 MW Solar Park resulting in up to 40% energy cost reduction 1- Mgmt estimations @ stability of crops, 2-Based on management estimates, 3- Define as infrastructure & equipment max production capacity 7 Phase 2 & 3 6 Ha (645,000 SQ. FT) Phase 1B 80,000 SQ.FT#9Khiron Health Services: Patients & Doctors Khiron's products are manufactured in INVIMA GMP-GEP compliant facilities in Colombia, and are standardized and stabilized according to the U.S. Pharmacopeia analytics standard (USP42) EAN KHIRON pipe Les Rich CBD 30 mg/ml KHIRON *As of the 1st of October & Beginning prescriptions late March 2020 Prepared han 1:1 (THC:CBD) 25 mg/ml 3,500 Medical Cannabis Prescriptions* 8 KHRON 6% Presereder Magistral Rich THC 20 mg/ml 27% 5% 324 2 8% KHIRON wapwan Nastal * Preparac Nagistral Khiron's actual medical cannabis patients in Colombia since April 2020 5% KHIRON LIFE SCIENCES CORP CBD 50 ml - 100 mg/ml -49% Chronic Pain Arthrosis Fibromyalgia Sleep Disorders, Anxiety & Depression Others Parkinson.#10Khiron's Approach in the Low-Touch Economy 6:12 Inicio SHOPPING CAR Rapidly adopted telehealth and online services for everyone's safety in a post COVID-19 world PREPARACIÓN MAGISTRAL DE EXTRACTO BALANCEADO THC:CBD 1:1- TETRAHIDROCAN NABINOL(THC) 1,2%, LTE CANNABIDIOL(C BD) 1,3% -12 MG/ML THC - 13 MG/ML CBD - TITULACIÓN DE LA DOSIS DE ACUERDO CON EFECTOS 1 TERAPEUTICOS - Frasco - 12 MG/ML http://doctorzerenia.com Mis citas Más More than 9,000 transactions in Sept 2020* 25 medical cannabis specialists prescribing 3 locations in Bogota 15% Telehealth Prescriptions Online doctor education, medical appointment & prescriptions Web-based or App-based E-payment platforms Home delivery of medical cannabis *Medical transactions include: consultation, surgical procedure, therapeutic support, diagnostic service, etc. 9/10 Patient Satisfaction 9 7:33 Zerenia Inicio Bienvenido(a) Paola En Doctor Zerenia podrás acceder al servicio de teleconsulta con doctores de diferentes especialidades y con opción de tratamiento con cannabis medicinal. Buscar por síntomas CLINICA DECUIDADO INTEGRADO CONSULTA PRIMERA VEZ - PROGRAMA CANNABIS... Inicio Zerenia CONSULTA CONTROL - PROGRAMA CANNABIS... Neuro Pediatría CLINICA DE CUIDADO KHIRON HIT SCIENCES CORP ... 46 Mis citas Zerenia CLINICA DE CUIDADO INTEGRADO CONSULTA CONTROL - PROGRAMA CANNABIS... SoyLocatel SOYLOCATEL70 Neuro Pediatría Más#11Medical Education to Drive Prescriptions Medical education is a continuous process, ensuring we connect doctors with patients in all our markets 2. te maal de Cantahs Marcial Madras Rib New P KHIRON MED TAHRAETE MEDICINAL dobra Spre Tecnológico de Monterrey KHIRON +1,500 Physicians trained online through Khiron's partnership with Tec of Monterrey (LatAm's 3rd most prominent university, No. 1 in Mexico) and MCCS in UK MES Medical CarusaDis Cincas Sociory LEVEL UP YOUR MEDICAL KNOWLEDGE! Course in safe and responsible prescribing of Medical Cannabis in the UK Dr. Maria Fernanda Arboleda Khiron's le national Director for Medical Services EXCLUSIVE FOR MEMBERS 10 KHIRON LIFE SCIENCES CORP Partnerships with more than 15 3rd party pain clinics and health centres for easy patient access across Colombia#12Khiron Enters the UK with Project Twenty21 In Q3/2020, Khiron began selling medical cannabis to patients in the UK through Project Twenty21 & expanded medical cannabis doctor education in partnership with Medical Cannabis Clinicians Society ("MCCS") 66.4 M population United Kingdom US$ 1.3 Billion TAM Medical cannabis 2024 ¹ The Herald: Young mum is first in Scotland to be prescribed cannabis 400,000 Medical cannabis patients by 2024¹ Project Twenty21 • Europe's 1st & largest national medical cannabis registry (chronic pain, epilepsy, PTSD, MS, substance abuse, anxiety). Goal to reach 20,000 patients by end of 2021 a to reach 1- Prohibition Partners - The UK Cannabis Report, January 2020 RC PSYCH ROYAL COLLEGE OF PSYCHIATRISTS KE MCCS An independent, clinician-led organization sharing guidance to lead the medical cannabis conversation in the UK. The program comprises access to Khiron's e-learning modules to help doctors prescribe medical cannabis for priority conditions including chronic pain, anxiety, cancer and epilepsy 11 7.3 Million People use CBD in the UK every year¹ THE BRITISH PAIN SOCIETY EXPERTISE WHERE IT MATTERS KHIRON LIFE SCIENCES CORP Drug Science PLEA For Quality of Life with Medical Cannabis MCS Medical Cannabis Clinicians Society#13Germany, largest market opportunity in Europe nimbus HEALTH In Q2/2020, Khiron signed distribution deal in Germany for medical cannabis imports and sales of branded EU GMP medical cannabis products, including medical education and marketing activities. 82.8 M population 50% of total medical cannabis sales in March 2020 were dry flower sales¹ US$ 8.7 Billion Germany TAM medical cannabis by 2028² US$ 43.9 M Reimbursements for medical cannabis in Q1 2020¹ 78,233 Prescriptions in Q1 2020¹ 1.0 Million Patients by 2024¹ Number of Applications Applications for Insurance Coverage of Medical Cannabis in Germany 100K 90K 80K 70K 60K 50K 40K 30K 20K 10K OK 1- https://mjbizdaily.com/insurance-covered-reimbursements-for-medical-cannabis-sets-record-in-germany/, 2- Prohibition Partners - The Germany Cannabis Report, October 2019 3- https://mjbizdaily.com/german-medical-cannabis-applications-for-insurance-reach-100000/ 12 Approved Cumulative No. of Approvals 2017 * Through June 2020 2018 KHIRON LIFE SCIENCES CORP 2019 3 2020*#14Latin America Leader: Peru DVINICO ARMACENTICE ill Vartal Creance caminore recorrerlo... TOHIRON ALIXEN 30 mg/ml ASTRAL Txtracto de Carvates Sativa 30 DON TOS KHIRON GLOBA MEDICAL ANNARS COMPANY Peru ● ● 32 Million Population 1-New Frontier Data - THE LATIN AMERICA REGIONAL 2019 INDUSTRY OUTLOOK, 2 - Mgmt Estimates, 3-Mgmt estimates from IMS Quantiles >3 Million potential patients³ 13 KHIRON LIFE SCIENCES CORP US$ 250M Peru medical cannabis TAM² 03/2020: Signs 2-year agreement with Farmacia Universal (10 locations) for product manufacture and distribution US$ 317/y Estimated annual patient out-of-pocket expenditure on medical cannabis 04/2020: Khiron obtains first license to import medical cannabis products into Peru 07/2020: Khiron receives all authorizations to commercialize low THC medical cannabis 10/2020: Khiron becomes first company to sell medical cannabis in Peru#15Latin America Leader: Brazil Brazil ● ● 210 Million Population As of August 2020, approximately 20,000 patients have been granted an authorization allowing them to import medical cannabis products in Brazil according to ANVISA. 3000 01/2020: Khiron obtains approval for compassionate care product import into Brazil by ANVISA 04/2020: Khiron closed deal with Medlive, a distributor serving 3,000 clinics and hospitals in the south of Brazil 2500 2000 Authorizations from ANVISA for Individual Patients to Import Non-registered Cannabis Products 1500 1000 US$ 4.7B Brazil medical cannabis TAM¹1 500 >24 Million potential patients³ 0 New Authorizations Renewals KHIRON LIFE SCIENCES CORP US$ 405/y Estimated annual patient out-of-pocket expenditure on medical cannabis² Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q2 2019 1-New Frontier Data - THE LATIN AMERICA REGIONAL 2019 INDUSTRY OUTLOOK, 2 - Mgmt Estimates, 3-Mgmt estimates from IMS Quantiles 4- https://mjbizdaily.com/individual-imports-of-cannabis-continue-to-grow-in-brazil/ 14 Q3 2019 Q4 2019 Q1 2020#16distinto We do it different 不同 KUIDA 1- Technavio Research, February 2020 KHIRON KUIDA ● Launched in Q4 2018 in Colombia KHIRON 11 SKUs, sold in 4 continents & 5 countries ● WELLBEING ● CANNABIS COSMECEUTICS JOIN THE WOMEN WHO CBDERM® DO IT DIFFERENT! 30% of sales through digital channels (Starting in May 2020) Q1 2020 sales increase of 18% compared to Q1 2019, with a GM of ± 60% 15 199 KUIDA KUIDA KUIDA 1157.. DHE KUIDA S kuidaskincare.com SVERI#17Khiron + Rappi: Beyond E-commerce In September 2020, Khiron + Rappi (largest unicorn in Latam) signed a landmark partnership to distribute Khiron's CPG product line, Kuida, exclusively throughout Rappi's platform across Latin America 7:52 KUIDA Q Search products or categories KUIDA Kuida Cdu: Bogotá Centro Check service fee and more ELCBD del Next delivery available: Today, 9 PM Hallways 0 Ciudado de Piel $44.900 KUIDA Crema Cor... 450 Mililitros ($99.78/... Add to Cart Ciudado de Piel $49.600 KUIDA Spray Relaj... 250 Mililitros ($198.4/. Add to Cart Cuidado Facial Go to Checkout l 4G 1- According to Apptopia Report G Cuidado Facial See all www. $19.900 Kuida Crema 30 mL ($663.33/ Add to Co See all $0 Rappi ● With the potential to build on the partnership over time across other business lines. 10 M Monthly active users¹ US$ 3,500 M Valuation • 6-month mutual exclusivity for CBD- cosmetics across all countries with Rappi presence México Marketing budget allocation to drive sales of the products 16 Guatemala Kuida is 1st CBD product line to launch exclusively on Multi-vertical apps anywhere El Salvador Belize Honduras Nicaragua Costa Rica Panamá Ecuador Colombia Perú Rappi KHIRON LIFE SCIENCES CORP Venezuela Guyana Chile Bolivia Suriname Guayana Francesa Paraguay Argentina Brasil 6 Uruguay#18A PATH TOWARDS GLOBAL GROWTH (Mexico Colombia IIIIIII K IIIIIII Peru 000 IIIII 100 Medical cannabis sales/ Prescription IIII UK SPAIN K K GERMANY Brazil [ D IIIIIII TITTY mm I m 17 [IIIIIIIIIIII ●●● Health Services/ Doctor Training K TID IIIII an 000 Kuida CBD CPG Sales IIIII D HONG KONG K#19Sustainability Matters COVID-19 RESPONSE 1) Provided the city of Bogota with PCR testing equipment to increase the city's testing capabilities 2) COVID-19 definite testing at Khiron clinics in partnership with accredited lab across Bogota ENVIRONMENT SOLAR PARK, DOIMA-IBAGUE 1) Implementation of recycling programs on substrate and irrigation to reduce waste 2) Delivery of packing material of site consumables to the community for recycling ~1MW UP TO 40% Energy Cost Reduction 18 KHIRON LIFE SCIENCES CORP SOCIAL RESPONSBILITY KHIRON 1) Donated nutritional kits to vulnerable families around our production site 2) Delivered medical supplies for the town's medical center#20A Diverse, Experienced Management team Alvaro Torres CEO Industrial Engineer (RPI), MBA (Georgetown University) 15+ years experience in top management of infrastructure sector in LatAm. Formerly with SNC-Lavalin building company's presence in Colombia. Overseen more than US$ 1 Billion infrastructure projects in development and completion Andres Galofre VP Business Development 15+ years of leadership experience in pharmaceutical marketing, brand management, and distribution of ethical drugs and consumer products in Latin America Led Advil launch in Colombia that reached 30% of domestic market share from inception Rodrigo Duran VP Khiron Med 17+ years of experience in CPG & Pharma marketing, sales and go-to-market strategies, managing teams, and bringing brands across the Latam markets Former manager executive of Team Food, Pfizer and Wyeth Elsa Navarro VP Khiron Wellbeing & Marketing More than 13 years of experience in international business, CPG marketing, brand management for international brands in skin care, personal care and other CPG categories Matt Murphy VP Compliance 25 years with the U.S. DEA. Served in variety of positions, including Chief of Pharmaceutical Investigations, prior to founding the Pharma Compliance Group 19 Joel Friedman - CPA, CA CFO . • KHIRON LIFE SCIENCES CORP 10+ years of international financial experience, including in the cannabis and mining industries Prior experience includes VP Finance at CannTrust Inc., Director of Finance at Primero Mining Corporation, in addition to progressively senior finance roles at Banro Corp and lamgold Corporation Tejinder Virk President - Khiron Europe 15 years of executive-level experience in the capital markets and cannabis industry Previously served as a Managing Director in Europe, for Canopy Growth Corp. Formerly Managing Director of Global Equity Products for BMO Capital Markets Rayet Harb VP Khiron Health Services 20+ years of experience in operations management, administration and technology, With extensive experience in the executive management of healthcare companies, on both segments: health insurance and healthcare delivery services CEO Sanitas USA, President Sanitas Mexico, VP Colsanitas . Juan Diego Alvarez VP Regulatory Affairs Ph.D., Law and public health, Tulaine University 10+ years of experience of legal experience in Colombian & Latam medical cannabis regulation. Appointed by Minister of Health to create and draft regulations for legalization of medical cannabis Franziska Katterbach CLO Khiron Europe 7 years of legal and regulatory expertise working within Europe's emerging cannabis industry Previously working for Dentons involved in high profile cannabis deals across multiple jurisdictions. Later served as Legal Director for Canopy's European operations#21Experienced Independent Board of Directors Global Branding, Project and Regional Business Expertise Chris Naprawa Chairman of the Board HIRO 20+ years of experience in institutional capital markets. Former partner at Sprott Capital Partners, Head of Equity Sales at Macquarie Canada, Head of Equity Sales and Trading at Dundee Securities and Managing Director at Primary Capital. Deborah Rosati Lead Director ● Over 30 years of experience, including in consumer, cannabis, private equity and venture capital. Vice Chair & Chair of the Audit Committee at cannabis authority Lift & Co (TSXV: LIFT). Founder & CEO of Women Get on Board, Former Chair of the Audit Committee at Sears Canada Inc., member of the Department Audit Committee at Correction Services Canada, and former Board member and Chair of the Audit Committee. at NexJ Systems Inc.. Alvaro Torres Co-founder & Director Industrial Engineer who built infrastructure projects in Colombia and LatAm. 20 KHIRON Ir ScirCS CORP Formerly with SNC Lavalin and successfully built an engineering and merchant banking firm. Alvaro Yañez Independent Director 15 years of legal experience in Colombia and internationally. Vicente Fox Independent Director Mexican businessman and politician who served as 55th President of Mexico. Former CEO Coca-Cola Mexico. Former Legal Manager of Frontera Energy (formerly known as "Pacific Exploration and Production").#22Capital Structure & Coverage DREAM UNLIMITED CORP (DRM) 09.90 0.00 TMX. Notes: 1) As at October 20, 2020 2) As at September 1, 2020 3) As at June 30, 2020 DESCARTES SYSTEMS GROUP INC (DSG) 0 39.23 0.00 Khiron Life Sciences Khiron Life Sciences TSXV: KHRN THE MARKET IS OPEN TMX TMX ENCANA CORPORATION (E 0 16.07 0.00 ANALYST COVERAGE TMX Basic Shares Outstanding¹ Recent Share Price (CAD)¹ Current Market Capitalization (CAD)¹ Aligned Management and Board² Warrants, Options and RSU's Outstanding (CAD) ² Weighted Average Strike Price for Warrants (CAD) ² Cash (CAD)³ Total assets minus goodwill & intangible (CAD) ³ 3 FIRM AltaCorp Capital Bryan, Garnier & Co. 21 ANALYST David M. Kideckel Nikolaas Faaes KHIRON LIFE SCIENCES CORP 118 million $0.45 $53 million 14% 12.9 million $2.31 $20 million $47 million#23Investment Highlights $ KHIRON LIFF SCIENCES CORP Estres Pureplay health & wellbeing company in the rapidly growing GLOBAL cannabis market Commercial sales of medical cannabis in 3 countries (Latam and Europe), targeting 5 countries at the end of 2020 Anchored by traditional clinical operations in Colombia for patient acquisition (450% QoQ RX growth in Q3 & 25 Prescribing doctors) Major infrastructure, cultivation, extraction, labs and clinics built out High insider ownership & no corporate debt 22 000#24FLANS KHIRON LIFE SCIENCES CORP Visit Khiron online at investors.khiron.ca and on Instagram @khironlife [email protected] T: +1 (786) 233-7411 23 Alvaro Torres CEO Bogotá, Colombia Email: [email protected] Chris Naprawa Chairman Toronto, ON, Canada Email: [email protected] Tejinder Virk E.U President London, Email: [email protected]